Navigation Links
Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
Date:7/29/2010

istory of use of these products."

Study Design

COR-I was a 56-week placebo-controlled, double-blind randomized trial enrolling patients whose body-mass index (BMI) was between 30-45 kg/m(2) for patients with uncomplicated obesity, or BMI 27-45 kg/m(2) with controlled hypertension or dyslipidemia, or both. 1742 patients were randomized to receive either Contrave32, Contrave16 (16mg naltrexone SR/360mg bupropion SR), or placebo in a 1:1:1 ratio. Thirty-four sites in the United States participated in the study.

About Contrave

Contrave is an investigational combination therapy believed to address both physiological and behavioral drivers of obesity. The two components of this combination therapy act in a complementary manner in the central nervous system. The central pathways targeted by this treatment are involved in controlling the balance of food intake and metabolism, and regulating reward-based eating behavior. In clinical trials, Contrave was shown to help obese patients initiate and sustain significant weight loss, improve important markers of cardiometabolic risk and increase ability to control eating. The U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011.

About the Contrave Clinical Development Program

All four trials in the COR Phase 3 program (COR-I, COR-II, COR-BMOD and COR-Diabetes) were randomized, double-blind, placebo-controlled trials. The co-primary endpoints were the proportion of patients achieving at least 5% weight loss and percent change in bo
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... ITASCA, Ill. , Feb. 26, 2015  Today ... paper, The psychological and physical side effects ... belief that opioid painkillers, such as Vicodin and Oxycontin, ... "More Americans overdose on prescription painkillers than on ... , president and CEO of NSC. "Yet, these medications ...
(Date:2/26/2015)... 2015  Mobility Ventures LLC, an AM General Company, ... America (NYSE: BAC ) that will make ... the revolutionary MV-1 - - the world,s first and ... to provide safe and comfortable transportation for all passengers ... to purchase a new MV-1 vehicle at the over ...
(Date:2/26/2015)... 2015 Legislation passed today by the House ... help prevent inappropriate prescriptions in Medicare Part D from ... of Medicare Act (PIMA) of 2014 , introduced by ... (R-TX) and Ranking Member Jim McDermott (D-WA), recognizes ... and implement the right policies, said the Pharmaceutical Care ...
Breaking Medicine Technology:National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2
... announced its board of directors has approved a cash dividend of ... company,s board of directors. At its meeting today, ... on Oct. 15 to shareholders of record on Oct. 1. The ... The board of directors also announced the election ...
... Vascular, Inc. (formerly known as Minnow Medical, Inc.), a ... announced today that it has completed a $23 million ... lead investor in the financing round was Edmond de ... in the financing was NY-based OrbiMed Advisors, CDF Dinova ...
Cached Medicine Technology:Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director 2Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director 3Vessix Vascular Completes $23 Million Financing 2Vessix Vascular Completes $23 Million Financing 3
(Date:2/28/2015)... (PRWEB) March 01, 2015 Heart diseases ... that 10 percent of urban adult population and 5 ... of heart diseases and 20-30 percent of them require ... heart ailments and coronary vascular diseases (CVD). , A ... a new market research report titled “Indian Coronary Stent ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... is offering a new special. Throughout all of ... , This service can help ... problems and pain. Patients may notice certain symptoms that ... relining. These symptoms include: , 1.    Pain, clicking, and ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 A study ... promising new gene therapy procedure for the treatment of ... in patients. Authored by Dr. Robert MacLaren, ... published in the Lancet Medical Journal on January 16, ... choroideremia, a rare genetic disorder that mostly affects men ...
(Date:2/28/2015)... February 28, 2015 Dr. Perry ... Coast area residents, recently announced a special offer for ... a treatment option for new and established patients at ... with a bright, white smile, Dr. Patel and his ... $299, marked down from the regular price of $450. ...
(Date:2/28/2015)... York, NY (PRWEB) February 28, 2015 On ... Phishing Kits Make It Easy For Scammers To Steal Your ... anyone can get their hands on a DIY phishing kit, ... But it also touched on another important point about how ... these kits are often implemented, “like compromising legitimate content management ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4
... FRIDAY, March 18 (HealthDay News) -- Obstructive sleep apnea may ... with enlarged prostates, a new study suggests. The study ... benign prostate enlargement (BPE) and reported nighttime urination (nocturia) at ... of same-age men who had no BPE and one or ...
... 18 (HealthDay News) -- Women in smoke-free homes and ... breast cancer, new research shows. U.S. researchers compared ... of breast cancer incidence and death. States with higher ... breast cancer deaths, particularly among younger premenopausal women. ...
... College of Radiology,s Imaging Network (ACRIN) and the ... (NCI) Clinical Trials Cooperative Group members, today announced ... programs. The groups plan to form ... new organization will include three areas of research ...
... with different terms to describe a clinical trial, parents were far ... called a "research study" than if it was called a "medical ... the former as safer, even though that was not necessarily the ... Human Research . Terms such as these are ...
... News) -- Anti-drug ads appear to be an effective way ... the United States, a new study has found. In ... Influence" anti-drug campaign, researchers analyzed the relationship between exposure to ... students in grades 8, 10 and 12. The campaign ...
... The federal Centers for Disease Control and Prevention ... Health & Hospitals System and Rush University Medical ... successful program aimed at preventing healthcare-associated infections, antibiotic ... The project, dubbed the Chicago Antimicrobial Resistance and ...
Cached Medicine News:Health News:Sleep Disorder May Spur Men to Head to Bathroom at Night 2Health News:Biomarker-driven science at the heart of new ACRIN-ECOG structure 2Health News:Biomarker-driven science at the heart of new ACRIN-ECOG structure 3Health News:Terminolgy matters in parents' willingness to enroll their children in research 2Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 2Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 3Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: